注射用苏维西塔单抗 | China Drugs ListSuvemcitug for injection | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 企业
- 江苏先声生物制药有限公司Jiangsu Simcere Biopharmaceutical Co., Ltd.
- 药品类型
- 生物药Biologic
- 治疗领域
- 肿瘤科Oncology
- 公开来源记录的适应症
- 苏维西塔单抗联合紫杉醇、多柔比星脂质体或拓扑替康用于铂耐药后接受过不超过 1 种系统治疗的成人复发性卵巢癌、输卵管癌或原发性腹膜癌的治疗。With paclitaxel, liposomal doxorubicin or topotecan for adults with recurrent ovarian, fallopian tube or primary peritoneal cancer who have received no more than one systemic treatment after becoming platinum-resistant.
- 适应症来源与口径
- 来源日期： 2025. 适应症转录自国家医保局公开的企业申报资料；不代表已核实完整的现行说明书。 新增适应症可能由较新的公告或申报资料支持，而非旧版完整说明书；请查看适应症来源。Source date(s): 2025. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label. Additional indications may be supported by newer announcements or submissions rather than the older full label; see the indication sources.
- 说明书信息局限
- 适应症已与官方公开申报资料核对。尚未取得完整原始说明书。Indications checked against an official public submission. The full original prescribing information is still unavailable.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 待逐一核查各市场。Market-by-market verification pending.
- 医保分类
- 已纳入国家医保（乙类）Included in national insurance (Category B)
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保限制
- 限铂耐药后接受过不超过1种系统治疗的成人复发性卵巢癌、输卵管癌或原发性腹膜癌的治疗。Restricted to adults with recurrent ovarian, fallopian tube or primary peritoneal cancer who have received no more than one systemic treatment after becoming platinum-resistant.
- 医保期限
- 2026-01-01 至 2027-12-312026-01-01 to 2027-12-31
- 医保核查说明
- 按成分／剂型名称精确或标准化匹配。报销仍取决于剂型及目录所列支付限制。Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.